Home / Healthcare / Streptococcus Pyogenes Infections - Pipeline Review, H1 2015

Streptococcus Pyogenes Infections - Pipeline Review, H1 2015

Published: Jan 2015 | No Of Pages: 42 | Published By: Global Markets Direct

Streptococcus Pyogenes Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Streptococcus Pyogenes Infections - Pipeline Review, H1 2015', provides an overview of the Streptococcus Pyogenes Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Streptococcus Pyogenes Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Streptococcus Pyogenes Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Streptococcus Pyogenes Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Streptococcus Pyogenes Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Streptococcus Pyogenes Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Streptococcus Pyogenes Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Streptococcus Pyogenes Infections Overview 6
Therapeutics Development 7
Pipeline Products for Streptococcus Pyogenes Infections - Overview 7
Pipeline Products for Streptococcus Pyogenes Infections - Comparative Analysis 8
Streptococcus Pyogenes Infections - Therapeutics under Development by Companies 9
Streptococcus Pyogenes Infections - Therapeutics under Investigation by Universities/Institutes 10
Streptococcus Pyogenes Infections - Pipeline Products Glance 11
Early Stage Products 11
Streptococcus Pyogenes Infections - Products under Development by Companies 12
Streptococcus Pyogenes Infections - Products under Investigation by Universities/Institutes 13
Streptococcus Pyogenes Infections - Companies Involved in Therapeutics Development 14
Absynth Biologics Limited 14
GlycoVaxyn AG 15
Helix BioMedix, Inc. 16
Novartis AG 17
Sumitomo Dainippon Pharma Co., Ltd. 18
Wellstat Vaccines, LLC 19
Streptococcus Pyogenes Infections - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
HB-1345 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SM-295291 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SM-369926 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
streptococcus [serotype A] vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
streptococcus [serotype A] vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
streptococcus pyogenes vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
streptococcus pyogenes vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
streptococcus pyogenes vaccine (30-valent) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
streptococcus vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Streptococcus Pyogenes Infections - Recent Pipeline Updates 39
Streptococcus Pyogenes Infections - Dormant Projects 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

Number of Products under Development for Streptococcus Pyogenes Infections, H1 2015 7
Number of Products under Development for Streptococcus Pyogenes Infections - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Streptococcus Pyogenes Infections - Pipeline by Absynth Biologics Limited, H1 2015 14
Streptococcus Pyogenes Infections - Pipeline by GlycoVaxyn AG, H1 2015 15
Streptococcus Pyogenes Infections - Pipeline by Helix BioMedix, Inc., H1 2015 16
Streptococcus Pyogenes Infections - Pipeline by Novartis AG, H1 2015 17
Streptococcus Pyogenes Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 18
Streptococcus Pyogenes Infections - Pipeline by Wellstat Vaccines, LLC, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Streptococcus Pyogenes Infections Therapeutics - Recent Pipeline Updates, H1 2015 39
Streptococcus Pyogenes Infections - Dormant Projects, H1 2015 40

Number of Products under Development for Streptococcus Pyogenes Infections, H1 2015 7
Number of Products under Development for Streptococcus Pyogenes Infections - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +